Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study

被引:13
作者
Martinelli, Ida [1 ]
Maino, Alberto [1 ]
Abbattista, Maria [1 ]
Bucciarelli, Paolo [1 ]
Passamonti, Serena M. [1 ]
Artoni, Andrea [1 ]
Gianniello, Francesca [1 ]
Peyvandi, Flora [1 ]
机构
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, A Bianchi Bosomi Hemophilia & Thrombosis Ctr, Via Pace 9, I-20122 Milan, Italy
关键词
Oral contraceptives; Venous thrombosis; Thrombophilia; Risk factors; Women's health; PROTHROMBIN GENE; THROMBOSIS; MUTATION;
D O I
10.1016/j.thromres.2016.03.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Oral contraceptive (OC) use increases the risk of venous thromboembolism (VTE), but the effect of duration of use remains to be elucidated. Patients and methods: This case-control study was aimed to investigate the duration of OC use on the risk of VTE according to women age, periods of use, prevalence of other risk factors and the role of thrombophilia abnormalities. Seven-hundred patients and 209 controls who used OC were stratified into short users (<= 1 year), long users (1 to 5 years), and very long users (>5 years). Results and conclusions: Compared to non-users, the odds ratio (OR) for VTE was 9.0 (95% CI 6.9-12.2) in short, 6.5 (95% CI 4.8-83.7) in long and 5.9 (95% CI 4.4-8.1) in very long users. The risk of VTE in short users was highest in women <= 30 years and in the first year of use (OR 13.1, 95% CI 7.7-22.4) and decreased afterward (OR 7.7, 95% CI 5.0-11.9). This trend was not observed in women >30 years. Compared to non-carriers and non-users, a joint effect of thrombophilia abnormalities and OC use on VTE risk was observed particularly in short users (OR 62.2, 95% CI 29.8-129.6), but also afterward (OR 25.4, 95% CI 16.5-39.2). Other transient risk factors for VTE were present in 25% of very long and 16% of short users. In conclusion, the risk of VTE in OC users decreases over time only before 30 years and in first users. Thrombophilia abnormalities strongly interact with the duration of OC use in determining VTE. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:153 / 157
页数:5
相关论文
共 20 条
[1]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[2]   Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects [J].
Bloemenkamp, KWM ;
Rosendaal, FR ;
Helmerhorst, FM ;
Vandenbroucke, JP .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) :49-52
[3]   ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN [J].
BLOEMENKAMP, KWM ;
ROSENDAAL, FR ;
HELMERHORST, FM ;
BULLER, HR ;
VANDENBROUCKE, JP .
LANCET, 1995, 346 (8990) :1593-1596
[4]   History of oral contraceptive drugs and their use worldwide [J].
Christin-Maitre, Sophie .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 27 (01) :3-12
[5]  
Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257
[6]   Cancer-associated thrombosis: updates and controversies [J].
Khorana, Alok A. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, :626-630
[7]   Hormonal contraception and risk of venous thromboembolism: national follow-up study [J].
Lidegaard, Ojvind ;
Lokkegaard, Ellen ;
Svendsen, Anne Louise ;
Agger, Carsten .
BRITISH MEDICAL JOURNAL, 2009, 339 :557-560
[8]  
Mannucci P. M., 1999, LAB TECHNIQUE THROMB
[9]   Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis [J].
Martinelli, I ;
Taioli, E ;
Bucciarelli, P ;
Akhavan, S ;
Mannucci, PM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) :700-703
[10]   Cerebral vein thrombosis [J].
Martinelli, Ida .
THROMBOSIS RESEARCH, 2013, 131 :S51-S54